Incidence age is bimodal for myalgic encephalomyelitis/chronic fatigue syndrome, with higher severity burden for early onset disease.
McGrath, Simon J, Hillier, Charles B, Dibble, Joshua J et al. · Oxford open immunology · 2026 · DOI
Quick Summary
This study of over 9,000 ME/CFS patients across Europe observed that the disease tends to appear at two distinct ages: around 16 years old and around 37 years old. Early-onset cases were associated with more severe illness, a stronger family history of ME/CFS, and more frequent infection triggers—particularly glandular fever. These findings were replicated in a separate UK dataset, though the study does not establish why these two peaks occur or prove a causal mechanism.
Why It Matters
This study identifies a previously underappreciated feature of ME/CFS epidemiology—two distinct age-of-onset clusters—which may point to different disease triggers or pathogenic mechanisms in adolescent versus middle-aged populations. For early-onset patients, the stronger link to infection (especially glandular fever) and higher severity burden suggests this subgroup may warrant distinct clinical attention and research focus.
Observed Findings
Two peaks in ME/CFS incidence age were observed: one around 16 years (SD 4.3) and one around 37 years (SD 10.5); multimodal onset age was statistically supported in 7 of 10 European countries examined.
Early-onset ME/CFS was associated with higher odds of severe or very severe disease (OR = 2.15, 95% CI [1.84–2.51]).
Infection as a reported trigger was 10 percentage points more common in early-onset than late-onset cases (p = 2.1 × 10⁻¹³).
First-degree relatives with ME/CFS were associated with increased odds of early-onset disease (OR = 1.43, 95% CI [1.25–1.63]).
Glandular fever or infectious mononucleosis was associated with higher odds in early-onset cases in a UK replication cohort (OR = 2.32, 95% CI [1.99–2.71]).
Inferred Conclusions
The authors propose that ME/CFS incidence follows a bimodal age distribution, suggesting distinct aetiological pathways or risk factor combinations for early versus late onset disease.
They interpret the higher infection-trigger prevalence and familial clustering in early-onset cases as suggestive of a different disease mechanism—possibly involving genetic predisposition and post-infectious triggering—in adolescents.
The association between early onset and greater severity is interpreted as indicating either a more aggressive disease course in younger patients or different underlying pathophysiology.
Remaining Questions
What This Study Does Not Prove
This cross-sectional study does not establish causation between infection, family history, or any other factor and ME/CFS onset or severity. It does not confirm a biological mechanism explaining the bimodal pattern. It cannot rule out recall bias in self-reported age of onset or trigger attribution, nor does it address whether the two peaks represent distinct disease entities or a single disease with heterogeneous presentation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
Why does ME/CFS incidence peak at precisely these two ages, and are the two groups biologically or mechanistically distinct?
What role does post-infectious immune dysregulation play in early-onset disease compared to late-onset, and are there differences in long-term outcomes?
Can prospective cohort studies with objective biomarkers clarify whether the bimodal pattern reflects true disease heterogeneity or ascertainment/recall artifacts?
What additional genetic or environmental factors interact with infection history to determine severity in early-onset cases?